4.7 Article

Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 19, Pages 14664-14701

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c01196

Keywords

-

Funding

  1. Natural Science Foundation of Jiangsu Province [SBK2016020485, BK20180573]
  2. National Natural Science Foundation of China [81502925]
  3. Double First-Class University project of China Pharmaceutical University [CPU2018GF02]
  4. National Innovation and Entrepreneurship Training Program for Undergraduate [202110316173]

Ask authors/readers for more resources

Secondary mutations of FLT3 pose a significant clinical challenge in FLT3 inhibitor resistance. A series of novel compounds, with compound 67 showing potent inhibitory activity against FLT3-ITD-positive AML cells and cells with various secondary mutations, may serve as a promising drug candidate for the treatment of FLT3-ITD-positive AML.
Secondary mutations of FLT3 have become the main mechanism of FLT3 inhibitor resistance that presents a significant clinical challenge. Herein, a series of pyrazole-3-amine derivatives were synthesized and optimized to overcome the common secondary resistance mutations of FLT3. The structure-activity relationship and molecular dynamics simulation studies illustrated that the ribose region of FLT3 could be occupied to help address the obstacle of secondary mutations. Among those derivatives, compound 67 exhibited potent and selective inhibitory activities against FLT3-ITD-positive acute myeloid leukemia (AML) cells and possessed equivalent potency against transformed BaF3 cells with a variety of secondary mutations. Besides, cellular mechanism assays demonstrated that 67 strongly inhibited phosphorylation of FLT3 and its downstream signaling factors, as well as induced cell cycle arrest and apoptosis in MV4-11 cells. In the MV4-11 xenograft models, 67 exhibited potent antitumor potency without obvious toxicity. Taken together, these results demonstrated that 67 might be a drug candidate for the treatment of FLT3-ITD-positive AML.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available